1
|
Nikas SP, Ji L, Liu Y, Georgiadis MO, Dopeshwarkar A, Straiker A, Kudalkar S, Sadybekov AV, Dvorakova M, Katritch V, Mackie K, Marnett L, Makriyannis A. Chiral Me-2-arachidonoyl Glycerols: The First Potent Endocannabinoid Glyceride Templates with Stability to COX-2. ACS Med Chem Lett 2024; 15:965-971. [PMID: 38894922 PMCID: PMC11181503 DOI: 10.1021/acsmedchemlett.4c00175] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/18/2024] [Revised: 05/16/2024] [Accepted: 05/21/2024] [Indexed: 06/21/2024] Open
Abstract
2-Arachidonoyl glycerol (2-AG) is the principal endogenously produced ligand for the cannabinoid CB1 and CB2 receptors (CBRs). The lack of potent and efficacious 2-AG ligands with resistance against metabolizing enzymes represents a significant void in the armamentarium of research tools available for studying eCB system molecular constituents and their function. Herein we report the first endocannabinoid glyceride templates with remarkably high potency and efficacy at CBRs. Two of our lead chiral 2-AG analogs, namely, (13S)- and (13R)-Me-2-AGs, potently inhibit excitatory neurotransmission via CB1 while they are endowed with excellent resistance to the oxidizing enzyme COX-2. Our SAR results are supported by docking studies of the key analog and 2-AG on the crystal structures of CB1.
Collapse
Affiliation(s)
- Spyros P. Nikas
- Center
for Drug Discovery and Department of Pharmaceutical Sciences, Northeastern University, Boston, Massachusetts 02115, United States
| | - Lipin Ji
- Center
for Drug Discovery and Department of Pharmaceutical Sciences, Northeastern University, Boston, Massachusetts 02115, United States
| | - Yingpeng Liu
- Center
for Drug Discovery and Department of Pharmaceutical Sciences, Northeastern University, Boston, Massachusetts 02115, United States
| | - Markos-Orestis Georgiadis
- Center
for Drug Discovery and Department of Pharmaceutical Sciences, Northeastern University, Boston, Massachusetts 02115, United States
| | - Amey Dopeshwarkar
- Department
of Psychological and Brain Sciences, Gill Center for Biomolecular
Science, Indiana University, Bloomington, Indiana 47405, United States
| | - Alex Straiker
- Department
of Psychological and Brain Sciences, Gill Center for Biomolecular
Science, Indiana University, Bloomington, Indiana 47405, United States
| | - Shalley Kudalkar
- Departments
of Biochemistry, Chemistry, and Pharmacology, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, United States
| | - Anastasiia V. Sadybekov
- Department
of Quantitative and Computational Biology, and Department of Chemistry,
Bridge Institute, Center for New Technologies in Drug Discovery and
Development, University of Southern California, Los Angeles, California 90089, United States
| | - Michaela Dvorakova
- Department
of Psychological and Brain Sciences, Gill Center for Biomolecular
Science, Indiana University, Bloomington, Indiana 47405, United States
| | - Vsevolod Katritch
- Department
of Quantitative and Computational Biology, and Department of Chemistry,
Bridge Institute, Center for New Technologies in Drug Discovery and
Development, University of Southern California, Los Angeles, California 90089, United States
| | - Ken Mackie
- Department
of Psychological and Brain Sciences, Gill Center for Biomolecular
Science, Indiana University, Bloomington, Indiana 47405, United States
| | - Lawrence Marnett
- Departments
of Biochemistry, Chemistry, and Pharmacology, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, United States
| | - Alexandros Makriyannis
- Center
for Drug Discovery and Department of Pharmaceutical Sciences, Northeastern University, Boston, Massachusetts 02115, United States
- Center
for Drug Discovery and Department of Chemistry and Chemical Biology, Northeastern University, Boston, Massachusetts 02115, United States
| |
Collapse
|
2
|
Simard M, Archambault AS, Lavoie JPC, Dumais É, Di Marzo V, Flamand N. Biosynthesis and metabolism of endocannabinoids and their congeners from the monoacylglycerol andN-acyl-ethanolamine families. Biochem Pharmacol 2022; 205:115261. [PMID: 36152677 DOI: 10.1016/j.bcp.2022.115261] [Citation(s) in RCA: 17] [Impact Index Per Article: 8.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2022] [Revised: 09/14/2022] [Accepted: 09/15/2022] [Indexed: 11/02/2022]
Abstract
The endocannabinoids 2-arachidonoyl-glycerol (2-AG) and N-arachidonoyl-ethanolamine (AEA) are eicosanoids implicated in numerous physiological processes like appetite, adipogenesis, inflammatory pain and inflammation. They mediate most of their physiological effect by activating the cannabinoid (CB) receptors 1 and 2. Other than directly binding to the CB receptors, 2-AG and AEA are also metabolized by most eicosanoid biosynthetic enzymes, yielding many metabolites that are part of the oxyendocannabinoidome. Some of these metabolites have been found in vivo, have the ability to modulate specific receptors and thus potentially influence physiological processes. In this review, we discuss the biosynthesis and metabolism of 2-AG and AEA, as well as their congeners from the monoacyl-glycerol and N-acyl-ethanolamine families, with a special focus on the metabolism by oxygenases involved in arachidonic acid metabolism. We highlight the knowledge gaps in our understanding of the regulation and roles the oxyendocannabinoidome mediators.
Collapse
Affiliation(s)
- Mélissa Simard
- Centre de recherche de l'Institut universitaire de cardiologie et de pneumologie de Québec, Département of médecine, Faculté de médecine, Université Laval, Québec City, QC G1V 4G5, Canada; Canada Excellence Research Chair on the Microbiome-Endocannabinoidome Axis in Metabolic Health (CERC-MEND), Université Laval, Québec City, QC G1V 0A6, Canada
| | - Anne-Sophie Archambault
- Centre de recherche de l'Institut universitaire de cardiologie et de pneumologie de Québec, Département of médecine, Faculté de médecine, Université Laval, Québec City, QC G1V 4G5, Canada; Canada Excellence Research Chair on the Microbiome-Endocannabinoidome Axis in Metabolic Health (CERC-MEND), Université Laval, Québec City, QC G1V 0A6, Canada; Present address: Department of Pathology and Laboratory Medicine, University of British Columbia / BC Children's Hospital Research Institute, Vancouver, British Colombia, Canada
| | - Jean-Philippe C Lavoie
- Centre de recherche de l'Institut universitaire de cardiologie et de pneumologie de Québec, Département of médecine, Faculté de médecine, Université Laval, Québec City, QC G1V 4G5, Canada; Canada Excellence Research Chair on the Microbiome-Endocannabinoidome Axis in Metabolic Health (CERC-MEND), Université Laval, Québec City, QC G1V 0A6, Canada
| | - Élizabeth Dumais
- Centre de recherche de l'Institut universitaire de cardiologie et de pneumologie de Québec, Département of médecine, Faculté de médecine, Université Laval, Québec City, QC G1V 4G5, Canada; Canada Excellence Research Chair on the Microbiome-Endocannabinoidome Axis in Metabolic Health (CERC-MEND), Université Laval, Québec City, QC G1V 0A6, Canada
| | - Vincenzo Di Marzo
- Centre de recherche de l'Institut universitaire de cardiologie et de pneumologie de Québec, Département of médecine, Faculté de médecine, Université Laval, Québec City, QC G1V 4G5, Canada; Canada Excellence Research Chair on the Microbiome-Endocannabinoidome Axis in Metabolic Health (CERC-MEND), Université Laval, Québec City, QC G1V 0A6, Canada; Endocannabinoid Research Group, Institute of Biomolecular Chemistry, Consiglio Nazionale Delle Ricerche (CNR), 80078 Pozzuoli, Italy; Institut sur la Nutrition et les Aliments Fonctionnels, Centre NUTRISS, École de Nutrition, Faculté des sciences de l'agriculture et de l'alimentation, Université Laval, Québec City, QC G1V 0A6, Canada; Joint International Unit between the Consiglio Nazionale delle Ricerche (Italy) and Université Laval (Canada) on Chemical and Biomolecular Research on the Microbiome and Its Impact on Metabolic Health and Nutrition (UMI-MicroMeNu)
| | - Nicolas Flamand
- Centre de recherche de l'Institut universitaire de cardiologie et de pneumologie de Québec, Département of médecine, Faculté de médecine, Université Laval, Québec City, QC G1V 4G5, Canada; Canada Excellence Research Chair on the Microbiome-Endocannabinoidome Axis in Metabolic Health (CERC-MEND), Université Laval, Québec City, QC G1V 0A6, Canada.
| |
Collapse
|
3
|
de Bus I, Witkamp R, Zuilhof H, Albada B, Balvers M. The role of n-3 PUFA-derived fatty acid derivatives and their oxygenated metabolites in the modulation of inflammation. Prostaglandins Other Lipid Mediat 2019; 144:106351. [PMID: 31260750 DOI: 10.1016/j.prostaglandins.2019.106351] [Citation(s) in RCA: 62] [Impact Index Per Article: 12.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/08/2019] [Accepted: 06/27/2019] [Indexed: 12/14/2022]
Abstract
Notwithstanding the ongoing debate on their full potential in health and disease, there is general consensus that n-3 PUFAs play important physiological roles. Increasing dietary n-3 PUFA intake results in increased DHA and EPA content in cell membranes as well as an increase in n-3 derived oxylipin and -endocannabinoid concentrations, like fatty acid amides and glycerol-esters. These shifts are believed to (partly) explain the pharmacological and anti-inflammatory effects of n-3 PUFAs. Recent studies discovered that n-3 PUFA-derived endocannabinoids can be further metabolized by the oxidative enzymes CYP-450, LOX and COX, similar to the n-6 derived endocannabinoids. Interestingly, these oxidized n-3 PUFA derived endocannabinoids of eicosapentaenoyl ethanolamide (EPEA) and docosahexaenoyl ethanolamide (DHEA) have higher anti-inflammatory and anti-proliferative potential than their precursors. In this review, an overview of recently discovered n-3 PUFA derived endocannabinoids and their metabolites is provided. In addition, the use of chemical probes will be presented as a promising technique to study the n-3 PUFA and n-3 PUFA metabolism within the field of lipid biochemistry.
Collapse
Affiliation(s)
- Ian de Bus
- Nutrition and Pharmacology Group, Division of Human Nutrition, Wageningen University & Research, Stippeneng 4, 6708 WE, Wageningen, the Netherlands; Laboratory of Organic Chemistry, Wageningen University & Research, Stippeneng 4, 6708 WE, Wageningen, the Netherlands
| | - Renger Witkamp
- Nutrition and Pharmacology Group, Division of Human Nutrition, Wageningen University & Research, Stippeneng 4, 6708 WE, Wageningen, the Netherlands
| | - Han Zuilhof
- Laboratory of Organic Chemistry, Wageningen University & Research, Stippeneng 4, 6708 WE, Wageningen, the Netherlands; School of Pharmaceutical Sciences and Technology, Tianjin University, 92 Weijin Road, Tianjin, PR China; Department of Chemical and Materials Engineering, King Abdulaziz University, Jeddah, Saudi Arabia
| | - Bauke Albada
- Laboratory of Organic Chemistry, Wageningen University & Research, Stippeneng 4, 6708 WE, Wageningen, the Netherlands.
| | - Michiel Balvers
- Nutrition and Pharmacology Group, Division of Human Nutrition, Wageningen University & Research, Stippeneng 4, 6708 WE, Wageningen, the Netherlands.
| |
Collapse
|
4
|
Liu Y, Ji L, Eno M, Kudalkar S, Li AL, Schimpgen M, Benchama O, Morales P, Xu S, Hurst D, Wu S, Mohammad KA, Wood JT, Zvonok N, Papahatjis DP, Zhou H, Honrao C, Mackie K, Reggio P, Hohmann AG, Marnett LJ, Makriyannis A, Nikas SP. ( R)- N-(1-Methyl-2-hydroxyethyl)-13-( S)-methyl-arachidonamide (AMG315): A Novel Chiral Potent Endocannabinoid Ligand with Stability to Metabolizing Enzymes. J Med Chem 2018; 61:8639-8657. [PMID: 30196704 DOI: 10.1021/acs.jmedchem.8b00611] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
The synthesis of potent metabolically stable endocannabinoids is challenging. Here we report a chiral arachidonoyl ethanolamide (AEA) analogue, namely, (13 S,1' R)-dimethylanandamide (AMG315, 3a), a high affinity ligand for the CB1 receptor ( Ki of 7.8 ± 1.4 nM) that behaves as a potent CB1 agonist in vitro (EC50 = 0.6 ± 0.2 nM). (13 S,1' R)-dimethylanandamide is the first potent AEA analogue with significant stability for all endocannabinoid hydrolyzing enzymes as well as the oxidative enzymes COX-2. When tested in vivo using the CFA-induced inflammatory pain model, 3a behaved as a more potent analgesic when compared to endogenous AEA or its hydrolytically stable analogue AM356. This novel analogue will serve as a very useful endocannabinoid probe.
Collapse
Affiliation(s)
- Yingpeng Liu
- Center for Drug Discovery and Department of Pharmaceutical Sciences , Northeastern University , Boston , Massachusetts 02115 , United States
| | - Lipin Ji
- Center for Drug Discovery and Department of Pharmaceutical Sciences , Northeastern University , Boston , Massachusetts 02115 , United States
| | - Marsha Eno
- Center for Drug Discovery and Department of Pharmaceutical Sciences , Northeastern University , Boston , Massachusetts 02115 , United States
| | - Shalley Kudalkar
- Departments of Biochemistry, Chemistry, and Pharmacology , Vanderbilt University School of Medicine , Nashville , Tennessee 37232 , United States
| | - Ai-Ling Li
- Department of Biological and Brain Sciences , Indiana University , Bloomington , Indiana 47405 , United States
| | - Marion Schimpgen
- Institute of Organic and Pharmaceutical Chemistry , National Hellenic Research Foundation , 48 Vass. Constantinou , Athens 116-35 , Greece
| | - Othman Benchama
- Center for Drug Discovery and Department of Pharmaceutical Sciences , Northeastern University , Boston , Massachusetts 02115 , United States
| | - Paula Morales
- Center for Drug Discovery, Department of Chemistry and Biochemistry , University of North Carolina at Greensboro , Greensboro , North Carolina 27402 , United States
| | - Shu Xu
- Departments of Biochemistry, Chemistry, and Pharmacology , Vanderbilt University School of Medicine , Nashville , Tennessee 37232 , United States
| | - Dow Hurst
- Center for Drug Discovery, Department of Chemistry and Biochemistry , University of North Carolina at Greensboro , Greensboro , North Carolina 27402 , United States
| | - Simiao Wu
- Center for Drug Discovery and Department of Pharmaceutical Sciences , Northeastern University , Boston , Massachusetts 02115 , United States
| | - Khadijah A Mohammad
- Center for Drug Discovery and Department of Pharmaceutical Sciences , Northeastern University , Boston , Massachusetts 02115 , United States
| | - JodiAnne T Wood
- Center for Drug Discovery and Department of Pharmaceutical Sciences , Northeastern University , Boston , Massachusetts 02115 , United States
| | - Nikolai Zvonok
- Center for Drug Discovery and Department of Pharmaceutical Sciences , Northeastern University , Boston , Massachusetts 02115 , United States
| | - Demetris P Papahatjis
- Institute of Organic and Pharmaceutical Chemistry , National Hellenic Research Foundation , 48 Vass. Constantinou , Athens 116-35 , Greece
| | - Han Zhou
- Center for Drug Discovery and Department of Pharmaceutical Sciences , Northeastern University , Boston , Massachusetts 02115 , United States
| | - Chandrashekhar Honrao
- Center for Drug Discovery and Department of Pharmaceutical Sciences , Northeastern University , Boston , Massachusetts 02115 , United States
| | - Ken Mackie
- Department of Biological and Brain Sciences , Indiana University , Bloomington , Indiana 47405 , United States
| | - Patricia Reggio
- Center for Drug Discovery, Department of Chemistry and Biochemistry , University of North Carolina at Greensboro , Greensboro , North Carolina 27402 , United States
| | - Andrea G Hohmann
- Department of Biological and Brain Sciences , Indiana University , Bloomington , Indiana 47405 , United States
| | - Lawrence J Marnett
- Departments of Biochemistry, Chemistry, and Pharmacology , Vanderbilt University School of Medicine , Nashville , Tennessee 37232 , United States
| | - Alexandros Makriyannis
- Center for Drug Discovery and Department of Pharmaceutical Sciences , Northeastern University , Boston , Massachusetts 02115 , United States.,Departments of Chemistry and Chemical Biology , Northeastern University , Boston , Massachusetts 02115 , United States
| | - Spyros P Nikas
- Center for Drug Discovery and Department of Pharmaceutical Sciences , Northeastern University , Boston , Massachusetts 02115 , United States
| |
Collapse
|